Adresse

Neversstraße 5, 56068 Koblenz
Tel.: +49 261 97 37 71 31
Fax: +49 261 97 38 58 07
info@drfresenpharma.de

Hotline Großhandel

Hotline Großhandel
+49 261 97 37 71 31

QM-Siegel

Dr. Fresen Pharma ist zertifiziert nach DIN EN ISO 9001:2015 und BS OHSAS 18001:2007

Publikationen

Putzker M, Dumitrescu, Gandrabur T, Klose T.
Transportul global în sistem „frigorific“ al produselor farmaceutice care necesită refrigerare și congelare; 15 ani de experiență în studii și practice
HEALTH, Anul 6, Revista Nr. 63, Aprilie-Mai 2019;18-20; ISBN 978-606-93639-2-8

Klose T, Putzker M.
Pharmaceutical logistics with the premium system for cold chain transport of clinicals trials, drugs and blood products
IPL Forum, Schloss Braunfels, 14.05.2019

Klose T, Putzker M.
Telepharmazie in öffentlichen Apotheken in Deutschland – ein zukunftweisendes Modell?
Springer Verlag, Apotheke und Marketing, 2018; 4-5 (https://www.apotheke-und-marketing.de/telepharmazie-2160551-ma_article_recommend.html?)

Putzker M, Dumitrescu M, Klose T.
Global cold chain transport of liquid and frozen pharmaceuticals: experience from 12 years of evaluation and daily routine.
Farmacia 2019, submitted for publication

Putzker M, Tomaselli R, Klose T.
Arbeitsschutz in öffentlichen Apotheken im Licht der neuen Arbeitsmedizinischen Vorsorgeverordnung
Springer Verlag, Apotheke und Marketing, 1-2017;11-14
(http://www.apotheke-und-marketing.de/arbeitsschutz-ganz-modern-1871151.html)

Klose T, von Deringer N, Köhl T, Lerchen C, Putzker M.
Patientenvorsorge – Ein Kurzrargeber.
Verlag Strödicke 2017, 2.Auflage, 49 Seiten, ISBN 978-3-00-055527-5

Klose T, Buchta O, Putzker M.
Drei Koblenzer entwickelten Smartphone-„app“ für die individuelle medizinische Versorgung: Chance auf Lebensqualität und Einsparungen.
Watterich Verlag, TMK 2016; 26:40-1

Klose T, Sarholz S, Himmerich S, Putzker M.
Hilfe ein Kind- Ein Kurzrargeber für „Wartung und Pflege“ – und darüber hinaus.
Verlag Strödicke 2016, 1. Auflage, 68 Seiten

Klose T, Wolf M, Buchta O, Putzker M.
iMedicplan for compliance: can it improve life?
EJOP 2016; 1/ Vol. 10

Klose T, Putzker M.
Internationaler Transport kühlkettenpflichtiger Arzneimittel unter Temperaturkonsistenz zur Umsetzung der aktuellen GDP-Richtlinie.
Onkologische Pharmazie, 18. Jahrgang; Nr. 02/2016

Woeste C, Klose T.
Die Einführung der Transportvalidierung.
8. NZW Dresden; 18.06.2016

Putzker M, Tomaselli R, Klose T.
Arbeitsschutz in öffentlichen Apotheken im Licht der Arbeitsmedizinischen Versorgeverordnung.
8. NZW Dresden; 17.06.2016

Klose T, Himmerich S, Putzker M, Zernack S, Trennheuser F.
Ernährung und Hautpflege bei Krebs. Ein Kurzratgeber.
Verlag Strödicke, 54 Seiten, 3. Auflage 07/2015

Klose T.
LOGISTICS with the „Best system in the world“ for cold chain transport of clinical trials, drugs and blood products
Delta T Jahrestagung 21./22.04.2015

Berger R, Dillender A, Domogalla K, Klose T, Nix U, Siedenkamp K.
Wege zu positiver Krankheitsbewältigung und menschlichen Wachstum
12. Tagung; Brustzentrum Marienhaus Klinikum Neuwied; 21.02.2015

Klose T, Putzker M.
Challenge for the new GDP policy: global validated cold chain transport (2-8° C) of clinical trials and drugs
EJOP 2014; 4/ Vol. 8

Wolf M, Putzker M, Klose T.
Smartphone „app“ for Compliance: Better quality of life for patients and significant savings in health care.
ASCO 2014

Klose T, Schenk J, Putzker M.
Novel care conception for cancer patients in Germany.
31. Deutscher Krebskongress 2014

Putzker M, Klose T.
Weltweit qualitätsgesicherter Transport von Blutprodukten
Siemens Symposium Würzburg, 20.06.2013

Klose T, Bochert H H, Pruss A, Roth WK, Bohnen H, Putzker M.
A transport system for temperature-sensitive pharmaceuticals and especially red blood cell concentrates for use in widely varying physical and climatic conditions worldwide.
Vox Sanguinis 2010;44-53

Klose T, Prokoph B, Seidel K, Schmidt M, Hourfar K, Putzker M.
Safe system for transport of blood samples at recommended temperature (2-8°C).
Clin. Lab. 2009;55:375-378

Putzker M, Seidel K, Schmidt M, Hourfar K, Friedrich I, Bohnen H, Klose T.
Temperature-stable transport of blood products across Europe on varying environmental demand: finally working with fresh frozen plasma (FFP) as well.
Clin. Lab. 2009;55:371-374

Klose T, Prokoph B, Seidel K, Schmidt M, Hourfar K, Putzker M.
Safe system for transport of blood samples at recommended temperature (2-8°C).
Transfus Med Hemother 2009;36(suppl 1):63

Hourfar K, Klose T, Putzker M, Sireis W, Gubbe K, Karl A, Tonn T, Mayr-Wohlfart U, Schrezenmeier H, Prokoph B, Ruester B, Seidel K, Hellmann I, Geusendam G, Siebert B, Seifried E, Schmidt M.
Stability of transfusion transmitted viruses in whole blood.
Transfus Med Hemother 2009;36(suppl 1):12

Putzker M, Seidel K, Schmidt M, Hourfar K, Friedrich I, Bohnen H, Klose T. Temperature-stable transport of blood products across Europe on varying environmental demand: finally working with fresh frozen plasma (FFP) as well.
Transfus Med Hemother 2009;36(suppl 1):63

Klose T, Putzker M, Pruß A, Fresen F, Borchert H-H.
Transport de produits pharmaceutiques: Un réglement unique en Europe?
Elsevier SAS: Actualités pharmaceutiques 2008;n°474:25-27

Klose T, Putzker M, Pruß A, Borchert H-H.
Novel System for worldwide qualified Transport of Red Blood Cells Concentrates (RBC) under Extreme Enviromental Conditions.
Clin. Lab. 2008;54:25-28

Клозе T, Путцкер M, Прусс A, Борхерт H-H.
Использование пассивных охлаждающих бокcов для транспортировки продуктов крови. Гemaтoлoия и трaнcфузиoлoгия.
Издaтeльcтво „Meдицинa“, (январь), 33-35

Putzker M, Klose T, Sönnichsen I, Eck D, Thöle A.
Optimierung der Hautantiseptik vor der Venenpunktion bei der Blutspende.
Wehrmed. Mschr 2008; Heft 5-6:159-164

Klose T, Putzker M, Pruß A, Bochert H.-H.
Novel system for worldwide qualified transport of red blood cell concentrates (RBC) on extreme environmental demand.
Transfus Med Hemother 2007;34(suppl1):63

Klose T, Wedekind K, Riggert J, van der Meer P-F, Heuft H-G, Perotti C.
Transfusionsmedizin: Aktuelles aus Forschung und Praxis.
Transfus Med Hemother 2006;33:544-45

Klose T, Kiesewetter H, Pruß A, Roth W-K, Bohnen H, Friedrich I, Eck D, Putzker M.
Influence of below atmospheric pressure on the pharmaceutical quality of red blood cell concentrates (RBCs) during transport and storage.
Clin. Lab. 2006;52:57-61

Klose T, Pruß A, Kiesewetter H, Roth W – K, Bohnen H, Putzker M.
Quality assurance for long lasting transports of red blood cell concentrates on extreme environmental demand.
Transfus Med Hemother 2004; 31:365-370

Klose T, Bohnen H, Putzker M.
Ensuring the quality of red blood cells during long lasting transport on extreme environmental demand.
Transfus Med Hemother 2004; 31(suppl 3):43

Klose T, Putzker M.
Thalassämie – Blut als Heilmittel.
Pharmazeutische Zeitung 2003;148:38-39

Skare J, Farley J, Strominger JL, Fresen KO, Cho MS, zur Hausen H.
Transformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H.
J Virol. 1985 Aug;55(2):286-97.

Cho MS, Fresen KO, zur Hausen H.
Multiplicity-dependent biological and biochemical properties of Epstein-Barr virus (EBV) rescued from non-producer lines after superinfection with P3HR-1 EBV.
Int J Cancer. 1980 Sep 15;26(3):357-63.

Bornkamm GW, Kaduk B, Kachel G, Schneider U, Fresen KO, Schwanitz G, Hermanek P.
Epstein-Barr virus-positive Burkitt’s lymphoma in a German woman during pregnancy.
Blut. 1980 Mar;40(3):167-77.

Fresen KO, Cho MS, Gissmann L, zur Hausen H.
NC37-R1 Epstein-Barr virus (EBV): a possible recombinant between intracellular NC37 viral DNA and superinfecting P3HR-1 EBV.
Intervirology. 1980;12(6):303-10.

zur Hausen H, Fresen KO.
Heterogeneity of Epstein-Barr virus.
Biochim Biophys Acta. 1979 Nov 30;560(3):343-53.

Fresen KO, Cho MS, zur Hausen H.
Recovery of transforming EBV from non-producer cells after superinfection with non-transforming P3HR-1 EBV.
Int J Cancer. 1978 Oct 15;22(4):378-83.

Fresen KO, Cho MS, zur Hausen H.
Heterogeneity of Epstein-Barr virus. IV. Induction of a specific antigen by EBV from two transformed marmoset cell lines in Ramos cells.
Int J Cancer. 1978 Aug 15;22(2):160-5.

zur Hausen H, Fresen KO, Bornkamm GW.
Epstein-Barr virus genomes and their biological functions: a review.
IARC Sci Publ. 1978;(24 Pt 1):3-10.

zur Hausen H, Fresen KO.
Heterogeneity of Epstein-Barr virus derived from P3HR-1 cells.
IARC Sci Publ. 1978;(20):391-6.

Fresen KO.
Biologische und immunologische Untersuchungen zur Differenzierung von Epstein-Barr-Virusstämmen
Springer, 1978

Heyden HW, Weber R, Stuckstedte H, Saal JG, Fresen KO.
Isoenzyme pattern of acid phosphatase in epstein-barr-virus-DNA positive permanent growing lymphoid cell lines (author’s transl).
Blut. 1977 Nov 22;35(5):395-404.

zur Hausen H, Fresen KO.
Heterogeneity of Epstein-Barr virus. II. Induction of early antigens (EA) by complementation.
Virology. 1977 Aug;81(1):138-43.

Fresen KO, Merkt B, Bornkamm GW, Hausen H.
Heterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction.
Int J Cancer. 1977 Mar 15;19(3):317-23.

Fresen KO, zur Hausen H.
Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
Proc Natl Acad Sci U S A. 1977 Jan;74(1):363-6.

Fresen KO, Hausen H.
Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
Int J Cancer. 1976 Feb 15;17(2):161-6.

Fresen KO, Illiger HJ.
Lectin-independent, irreversible redistribution of concanavalin A receptors on influenza virus infected Ehrlich ascites tumor cells.
Arch Gesamte Virusforsch. 1974;44(4):377-85.

Fresen KO, Dübendorfer A.
Electrokinetic behavoir of Ehrlich ascites tumor cells following infection with oncolytic influenza viruses.
Pathol Microbiol (Basel). 1974;40(3):227-8.

Fresen KO.
Physico-chemical changes of the cell surface of Ehrlich ascites tumour cells following infection with oncolytic influenza virus.
Zentralbl Bakteriol Orig A. 1974;227(1-4):409-13.

Fresen KO, Dübendorfer A.
Physicochemical membrane changes in Ehrlich ascites tumor cells infected with oncolytic influenza virus.
Arch Gesamte Virusforsch. 1973;41(3):267-76.

Fresen KO, Vogt A.
Ultrastructural localization of peroxidase-labelled nephrotoxic antibodies after intravenous application.
Exp Pathol (Jena). 1973;8(4):276-82.

Fresen KO, Vogt A.
Hemolytic activity of antibody to sheep red cells conjugated to ferritin.
Med Microbiol Immunol. 1971;157(1):24-31.

Moppert J, Fresen KO.
Experimental glomerulonephritis and glomerulonephrosis in the mouse following repeated ovalbumin injections. A light, fluroescence and electron microscopic study.
Virchows Arch Pathol Anat Physiol Klin Med. 1967;342(4):304-18.

Fresen KO.
Experimentelle Glomerulonephritis und Glomerulonephrose bei der Maus nach wiederholten Ovalbumininjektionen: Eine licht-, fluoreszenz- u. elektronenoptische Untersuchung,
Springer, 1967

Skare J, Farley J, Strominger JL, Fresen KO, Cho MS, zur Hausen H.
Transformation by Epstein-Barr virus requires DNA sequences in the region of BamHI fragments Y and H.
J Virol. 1985 Aug;55(2):286-97.

Cho MS, Fresen KO, zur Hausen H.
Multiplicity-dependent biological and biochemical properties of Epstein-Barr virus (EBV) rescued from non-producer lines after superinfection with P3HR-1 EBV.
Int J Cancer. 1980 Sep 15;26(3):357-63.

Bornkamm GW, Kaduk B, Kachel G, Schneider U, Fresen KO, Schwanitz G, Hermanek P.
Epstein-Barr virus-positive Burkitt’s lymphoma in a German woman during pregnancy.
Blut. 1980 Mar;40(3):167-77.

Fresen KO, Cho MS, Gissmann L, zur Hausen H.
NC37-R1 Epstein-Barr virus (EBV): a possible recombinant between intracellular NC37 viral DNA and superinfecting P3HR-1 EBV.
Intervirology. 1980;12(6):303-10.

zur Hausen H, Fresen KO.
Heterogeneity of Epstein-Barr virus.
Biochim Biophys Acta. 1979 Nov 30;560(3):343-53.

Fresen KO, Cho MS, zur Hausen H.
Recovery of transforming EBV from non-producer cells after superinfection with non-transforming P3HR-1 EBV.
Int J Cancer. 1978 Oct 15;22(4):378-83.

Fresen KO, Cho MS, zur Hausen H.
Heterogeneity of Epstein-Barr virus. IV. Induction of a specific antigen by EBV from two transformed marmoset cell lines in Ramos cells.
Int J Cancer. 1978 Aug 15;22(2):160-5.

zur Hausen H, Fresen KO, Bornkamm GW.
Epstein-Barr virus genomes and their biological functions: a review.
IARC Sci Publ. 1978;(24 Pt 1):3-10.

zur Hausen H, Fresen KO.
Heterogeneity of Epstein-Barr virus derived from P3HR-1 cells.
IARC Sci Publ. 1978;(20):391-6.

Fresen KO.
Biologische und immunologische Untersuchungen zur Differenzierung von Epstein-Barr-Virusstämmen
Springer, 1978

Heyden HW, Weber R, Stuckstedte H, Saal JG, Fresen KO.
Isoenzyme pattern of acid phosphatase in epstein-barr-virus-DNA positive permanent growing lymphoid cell lines (author’s transl).
Blut. 1977 Nov 22;35(5):395-404.

zur Hausen H, Fresen KO.
Heterogeneity of Epstein-Barr virus. II. Induction of early antigens (EA) by complementation.
Virology. 1977 Aug;81(1):138-43.

Fresen KO, Merkt B, Bornkamm GW, Hausen H.
Heterogeneity of Epstein-Barr virus originating from P3HR-1 cells. I. Studies on EBNA induction.
Int J Cancer. 1977 Mar 15;19(3):317-23.

Fresen KO, zur Hausen H.
Transient induction of a nuclear antigen unrelated to Epstein-Barr nuclear antigen in cells of two human B-lymphoma lines converted by Epstein-Barr virus.
Proc Natl Acad Sci U S A. 1977 Jan;74(1):363-6.

Fresen KO, Hausen H.
Establishment of EBNA-expressing cell lines by infection of Epstein-Barr virus (EBV)-genome-negative human lymphoma cells with different EBV strains.
Int J Cancer. 1976 Feb 15;17(2):161-6.

Fresen KO, Illiger HJ.
Lectin-independent, irreversible redistribution of concanavalin A receptors on influenza virus infected Ehrlich ascites tumor cells.
Arch Gesamte Virusforsch. 1974;44(4):377-85.

Fresen KO, Dübendorfer A.
Electrokinetic behavoir of Ehrlich ascites tumor cells following infection with oncolytic influenza viruses.
Pathol Microbiol (Basel). 1974;40(3):227-8.

Fresen KO.
Physico-chemical changes of the cell surface of Ehrlich ascites tumour cells following infection with oncolytic influenza virus.
Zentralbl Bakteriol Orig A. 1974;227(1-4):409-13.

Fresen KO, Dübendorfer A.
Physicochemical membrane changes in Ehrlich ascites tumor cells infected with oncolytic influenza virus.
Arch Gesamte Virusforsch. 1973;41(3):267-76.

Fresen KO, Vogt A.
Ultrastructural localization of peroxidase-labelled nephrotoxic antibodies after intravenous application.
Exp Pathol (Jena). 1973;8(4):276-82.

Fresen KO, Vogt A.
Hemolytic activity of antibody to sheep red cells conjugated to ferritin.
Med Microbiol Immunol. 1971;157(1):24-31.

Moppert J, Fresen KO.
Experimental glomerulonephritis and glomerulonephrosis in the mouse following repeated ovalbumin injections. A light, fluroescence and electron microscopic study.
Virchows Arch Pathol Anat Physiol Klin Med. 1967;342(4):304-18.

Fresen KO.
Experimentelle Glomerulonephritis und Glomerulonephrose bei der Maus nach wiederholten Ovalbumininjektionen: Eine licht-, fluoreszenz- u. elektronenoptische Untersuchung,
Springer, 1967